

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 1, 2024

## P815

RRID:CVCL\_2154

Type: Cell Line

### Proper Citation

(RRID:CVCL\_2154)

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2154](https://web.expasy.org/cellosaurus/CVCL_2154)

**Proper Citation:** (RRID:CVCL\_2154)

**Description:** Cell line P815 is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Sex:** Male

**Disease:** Mouse mast cell neoplasm

**Defining Citation:** [PMID:1234049](#), [PMID:3792703](#), [PMID:4208429](#), [PMID:7513208](#), [PMID:10210327](#), [PMID:18432777](#), [PMID:25277546](#), [PMID:31220119](#)

**Comments:** Breed/subspecies: DBA/2., Omics: SNP array analysis., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** P815

**Synonyms:** P-815, P 815

**Cross References:** BTO:BTO:0000985, CLO:CLO\_0008340, CLO:CLO\_0008341, CLO:CLO\_0050217, CLDB:cl3784, CLDB:cl3785, CLDB:cl5244, ATCC:TIB-64, BCRC:60178, BCRJ:0200, BioSample:SAMN11397663, CCRID:1101MOU-PUMC000114, CCRID:3101MOUSCSP516, CCRID:3101MOUTCM12, CCRID:4201MOU-CCTCC00608, CCTCC:GDC0608, ChEMBL-Cells:ChEMBL3307568, ChEMBL-Targets:ChEMBL614226,

CLS:400242, DSMZ:ACC-1, DSMZCellDive:ACC-1, IZSLER:BS TCL 118, JCRB:IFO50029, JCRB:JCRB0078, KCB:KCB 93032YJ, Lonza:187, NCBI\_Iran:C550, PubChem\_Cell\_line:CVCL\_2154, RCB:RCB1167, TKG:TKG 0168, Wikidata:Q54937317

**ID:** CVCL\_2154

---

## Ratings and Alerts

No rating or validation information has been found for P815.

**Warning:** Discontinued: JCRB; IFO50029

Breed/subspecies: DBA/2., Omics: SNP array analysis., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 233 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Kamnev A, et al. (2024) Coordinated ARP2/3 and glycolytic activities regulate the morphological and functional fitness of human CD8+ T cells. *Cell reports*, 43(3), 113853.

Takheaw N, et al. (2023) Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms. *Cells*, 12(6).

Kalinina A, et al. (2023) Unique features of the TCR repertoire of reactivated memory T cells in the experimental mouse tumor model. *Computational and structural biotechnology journal*, 21, 3196.

Wu T, et al. (2023) Exploring plant polyphenols as anti-allergic functional products to manage the growing incidence of food allergy. *Frontiers in nutrition*, 10, 1102225.

Yue J, et al. (2023) Mast cell activation mediates blood-brain barrier impairment and cognitive dysfunction in septic mice in a histamine-dependent pathway. *Frontiers in immunology*, 14, 1090288.

Raman SNT, et al. (2023) Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses. *Emerging microbes & infections*, 12(1), 2192821.

Ye X, et al. (2023) Characterization of the Molecular Diversity and Degranulation Activity of Mastoparan Family Peptides from Wasp Venoms. *Toxins*, 15(5).

Kotzur R, et al. (2023) Eradication of CD48-positive tumors by selectively enhanced YTS cells harnessing the lncRNA NeST. *iScience*, 26(8), 107284.

Jiang P, et al. (2023) Mast cell stabilization: new mechanism underlying the therapeutic effect of intense pulsed light on rosacea. *Inflammation research : official journal of the European Histamine Research Society ... [et al.]*, 72(1), 75.

Bailey C, et al. (2023) Genetic and pharmaceutical targeting of HIF1 $\alpha$  allows combination immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease. *Cell reports. Medicine*, 4(11), 101236.

Widyagarini A, et al. (2022) VSIG4/CRIg directly regulates early CD8 $^{+}$  T cell activation through its counter-receptor in a narrow window. *Biochemical and biophysical research communications*, 614, 100.

Kristensen AB, et al. (2022) Phenotypic and functional characteristics of highly differentiated CD57+NKG2C $^{+}$  NK cells in HIV-1-infected individuals. *Clinical and experimental immunology*, 210(2), 163.

Zöphel D, et al. (2022) Faster cytotoxicity with age: Increased perforin and granzyme levels in cytotoxic CD8 $^{+}$  T cells boost cancer cell elimination. *Aging cell*, 21(8), e13668.

Falco M, et al. (2022) Epitope characterization of a monoclonal antibody that selectively recognizes KIR2DL1 allotypes. *HLA*, 100(2), 107.

Guo Z, et al. (2022) Overexpression of DAPK1-mediated inhibition of IKK $\alpha$ /CSN5/PD-L1 axis enhances natural killer cell killing ability and inhibits tumor immune evasion in gastric cancer. *Cellular immunology*, 372, 104469.

Maruhashi T, et al. (2022) Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. *Immunity*, 55(5), 912.

Valenzuela-Vázquez L, et al. (2022) NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemia. *Frontiers in oncology*, 12, 1023510.

Wen T, et al. (2022) NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. *Cancer immunology research*, 10(2), 162.

Ren X, et al. (2022) Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity. *The Journal of clinical investigation*, 132(22).

Linke A, et al. (2022) Antigen Cross-Presentation by Murine Proximal Tubular Epithelial Cells Induces Cytotoxic and Inflammatory CD8 $^{+}$  T Cells. *Cells*, 11(9).